Increasing evidence supports that lung cancer patients with coexistence of COPD might respond better to immunotherapy, which can partially be attributed to the fact that the expression of immune checkpoint proteins PD-1 and PD-L1 is dysregulated in COPD patients [14]. Here, PDCD1 is linked to lung carcinoma.